Aquyre Biosciences Inc., formerly known as Lltech, raised $19,945,534 in a series A2 preferred stock financing round to fund commercialization of its Celtivity system for on-site adequacy assessments of tissue biopsies. Ceros Financial Services acted as placement agent for more than $17.14 million of the funds raised in this round as part of its recently announced commitment to raise $100 million in the next 12 months for investment in early-stage medical technology and medical device companies.
Bristol Myers Squibb Co. has completed a $20 million equity investment in Compugen Ltd., part of an ongoing expansion a collaboration between the companies to combine their medicines for the potential benefit of patients with solid tumors.
PERTH, Australia – Radiopharm Theranostics Ltd. raised AU$50 million (US$36.4 million) in an oversubscribed IPO to advance its platform of radiopharmaceutical products for both diagnostic and therapeutic uses.
Chroma Medicine Inc. emerged from stealth with $125 million in series A financing and high ambitions to rewrite the rules of genomic medicine by modulating the epigenetic status of target genes in order to switch expression on or off and thereby achieve therapeutic outcomes.
SK Biopharmaceuticals Co. Ltd. has launched a central nervous system-focused biotech company called Ignis Therapeutics Ltd. with a $180 million series A round led by 6 Dimensions Capital L.P. The financing of the new Shanghai-based company represents the largest series A investment in China’s biopharma industry in 2021, according to the two founding companies. KB Investment Co. Ltd, WTT investment Ltd., HBM Healthcare Investments AG and Goldman Sachs Group Inc. also participated in the round.
PERTH, Australia – Australia’s Medical Research Future Fund is pumping AU$40 million (US$29 million) into a national biotech incubator program called CUREator to fund early stage novel therapeutics and preclinical medical research.
RSS
